The APOBEC3 family of retroelement restriction factors

Current Topics in Microbiology and Immunology

Volumn 371, Issue , 2013, Pages 1-27

  Refsland, Eric W ^a,b   Harris, Reuben S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3 INHIBITOR; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3C; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3D; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; CELL ENZYME; COMPLEMENTARY DNA; CYTIDINE DEAMINASE; CYTOSINE; DEAMINASE; DNA DEAMINASE; DOUBLE STRANDED DNA; ENZYME INHIBITOR; MESSENGER RNA; NUCLEIC ACID; RESTRICTION ENDONUCLEASE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; URACIL; VIRUS DNA; CYTOSINE DEAMINASE;

ARTICLE; CATALYSIS; DEAMINATION; ENZYME ACTIVITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE MUTATION; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR EVOLUTION; NONHUMAN; NUCLEIC ACID METABOLISM; PARASITE; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN SECONDARY STRUCTURE; RETROPOSON; RNA EDITING; VERTEBRATE; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; ANIMAL; ANTIBODY SPECIFICITY; IMMUNOLOGY; MUTAGENESIS; PHYSIOLOGY; REVIEW;

HUMAN IMMUNODEFICIENCY VIRUS 1; VERTEBRATA;

ANIMALS; ANTIBODY DIVERSITY; CYTOSINE DEAMINASE; HIV-1; HUMANS; IMMUNITY, INNATE; MUTAGENESIS;

EID: 84882417741     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-37765-5_1     Document Type: Article

References (212)

1. Abudu A, Takaori-Kondo A, Izumi T et al (2006) Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr Biol 16:1565-1570 (Pubitemid 44142982)
2. Agranat L, Raitskin O, Sperling J, Sperling R (2008) The editing enzyme ADAR1 and the mRNA surveillance protein hUpf1 interact in the cell nucleus. Proc Natl Acad Sci USA 105:5028-5033 (Pubitemid 351738504)
3. Aguiar RS, Lovsin N, Tanuri A, Peterlin BM (2008) Vpr.A3A chimera inhibits HIV replication. J Biol Chem 283:2518-2525
4. Albin JS, Harris RS (2010) Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 12:e4
5. Albin JS, LaRue RS, Weaver JA et al (2010) A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem 285:40785-40792
6. Alce TM, Popik W (2004) APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 279:34083-34086 (Pubitemid 39318027)
7. Ali A, Wang J, Nathans RS, Cao H, Sharova N, Stevenson M, Rana TM (2012) Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication. ChemMedChem 7:1217-1229
8. Anwar F, Davenport MP, Ebrahimi D (2013) Footprint of APOBEC3 on the genome of retrotransposons. J Virol (in press)
9. Betts SD, Hachigian TM, Pichersky E, Yocum CF (1994) Reconstitution of the spinach oxygenevolving complex with recombinant Arabidopsis manganese-stabilizing protein. Plant Mol Biol 26:117-130 (Pubitemid 2158052)
10. Bishop KN, Holmes RK, Malim MH (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80:8450-8458 (Pubitemid 44384857)
11. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14:1392-1396 (Pubitemid 39081643)
12. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4:e1000231
13. Bogerd HP, Cullen BR (2008) Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 14:1228-1236 (Pubitemid 351717501)
14. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR (2006a) APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 34:89-95 (Pubitemid 43167918)
15. Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, Moran JV, Cullen BR (2006b) Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci USA 103:8780-8785 (Pubitemid 43878096)
16. Bohn M-F, Shandilya SMD, Albin JS, Kouno T, Anderson BD, McDougle RM, Carpenter MA, Rathore A, Evans L, Davis AN, Zhang J, Lu Y, Somasundaran M, Matsuo H, Harris RS & Schiffer CA (2013) Crystal structure of the HIV-1 Vif-binding, catalytically active domain of the DNA cytosine deaminase APOBEC3F. Structure, in press.
17. Bonvin M, Achermann F, Greeve I et al (2006) Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43:1364-1374 (Pubitemid 43980116)
18. Bransteitter R, Pham P, Scharff MD, Goodman MF (2003) Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci USA 100:4102-4107 (Pubitemid 36418164)
19. Brass AL, Dykxhoorn DM, Benita Y et al (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921-926 (Pubitemid 351263756)
20. Britan-Rosich E, Nowarski R, Kotler M (2011) Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif. J Mol Biol 410:1065-1076
21. Browne EP, Allers C, Landau NR (2009) Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 387:313-321
22. Burnett A, Spearman P (2007) APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNAdependent process requiring the NC basic linker. J Virol 81:5000-5013 (Pubitemid 46744412)
23. Burns MB, Lackey L, Carpenter MA et al (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:366-370
24. Caride E, Brindeiro RM, Kallas EG, de Sa CA, Eyer-Silva WA, Machado E, Tanuri A (2002) Sexual transmission of HIV-1 isolate showing G→A hypermutation. J Clin Virol 23:179-189 (Pubitemid 32930093)
25. Carmi S, Church GM, Levanon EY (2011) Large-scale DNA editing of retrotransposons accelerates mammalian genome evolution. Nat Commun 2:519
26. Carpenter MA, Rajagurubandara E, Wijesinghe P, Bhagwat AS (2010) Determinants of sequence-specificity within human AID and APOBEC3G. DNA Repair 9:579-587
27. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L (2004) The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 279:33177-33184 (Pubitemid 39062962)
28. Chan L (1992) Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. JBiol Chem 267:25621-25624 (Pubitemid 23013946)
29. Chen H, Lilley CE, Yu Q et al (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 16:480-485 (Pubitemid 43343708)
30. Chen KM, Harjes E, Gross PJ et al (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452:116-119 (Pubitemid 351355093)
31. Chen YJ, Li M, Carpenter MA, McDougle RM, Macdonald PJ, Harris RS, Mueller JD (2013) APOBEC3 multimerization correlates with HIV-1 restriction activity in living cells. J Mol Biol (in preparation)
32. Chiu YL, Witkowska HE, Hall SC et al (2006) High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci USA 103:15588-15593 (Pubitemid 44625636)
33. Conticello SG (2008) The AID/APOBEC family of nucleic acid mutators. Genome Biol 9:229
34. Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13:2009-2013 (Pubitemid 37425213)
35. Conticello SG, Langlois MA, Neuberger MS (2007a) Insights into DNA deaminases. Nat Struct Mol Biol 14:7-9 (Pubitemid 46067415)
36. Conticello SG, Langlois MA, Yang Z, Neuberger MS (2007b) DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol 94:37-73 (Pubitemid 46856607)
37. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS (2005) Evolution of the AID/APOBEC family of polynucleotide (deoxy) cytidine deaminases. Mol Biol Evol 22:367-377 (Pubitemid 40130201)
38. Dang Y, Siew LM, Wang X, Han Y, Lampen R, Zheng YH (2008) Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem 283:11606-11614
39. Dang Y, Wang X, Esselman WJ, Zheng YH (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 80:10522-10533 (Pubitemid 44628899)
40. Delebecque F, Suspene R, Calattini S et al (2006) Restriction of foamy viruses by APOBEC cytidine deaminases. J Virol 80:605-614 (Pubitemid 43062873)
41. Di Noia J, Neuberger MS (2002) Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 419:43-48 (Pubitemid 34987864)
42. Di Noia JM, Neuberger MS (2007) Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 76:1-22
43. Doehle BP, Schäfer A, Cullen BR (2005a) Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339:281-288 (Pubitemid 41169795)
44. Doehle BP, Schafer A, Wiegand HL, Bogerd HP, Cullen BR (2005b) Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol 79:8201-8207 (Pubitemid 40853523)
45. Dutko JA, Schafer A, Kenny AE, Cullen BR, Curcio MJ (2005) Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr Biol 15:661-666
46. Esnault C, Heidmann O, Delebecque F et al (2005) APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433:430-433 (Pubitemid 40203324)
47. Esnault C, Millet J, Schwartz O, Heidmann T (2006) Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res 34:1522-1531
48. Fisher AG, Ensoli B, Ivanoff L et al (1987) The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237:888-893 (Pubitemid 17128277)
49. Fitzgibbon JE, Mazar S, Dubin DT (1993) A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res Hum Retroviruses 9:833-838 (Pubitemid 24017237)
50. Furukawa A, Nagata T, Matsugami A et al (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO j 28:440-451
51. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J (1992) Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 66:6489-6495
52. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN (2008) Role of APOBEC3G/Fmediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 82:3125-3130 (Pubitemid 351329200)
53. Gerber AP, Keller W (1999) An adenosine deaminase that generates inosine at the wobble position of tRNAs. Science 286:1146-1149
54. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Opi S, Takeuchi H, Strebel K (2008) HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology 372:136-146 (Pubitemid 351215461)
55. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K (2007) Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4:61
56. Grosjean H (2009) DNA and RNA modification enzymes: structure, mechanism, function and evolution.Landes Bioscience, Austin
57. Haché G, Liddament MT, Harris RS (2005) The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. Journal Bio Chem 280:10920-10924 (Pubitemid 40418393)
58. Haché G, Mansky LM, Harris RS (2006) Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev 8:148-157 (Pubitemid 44614032)
59. Harari A, Ooms M, Mulder LC, Simon V (2009) Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol 83:295-303
60. Harris RS (2008) Enhancing immunity to HIV through APOBEC. Nat Biotechnol 26:1089-1090
61. Harris RS, Bishop KN, Sheehy AM et al (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809 (Pubitemid 36724943)
62. Harris RS, Hultquist JF, Evans DT (2012) The restriction factors of human immunodeficiency virus. J Bio Chem 287:40875-40883
63. Harris RS, Liddament MT (2004) Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4:868-877 (Pubitemid 39490762)
64. Harris RS, Petersen-Mahrt SK, Neuberger MS (2002) RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 10:1247-1253 (Pubitemid 35453840)
65. Holden LG, Prochnow C, Chang YP et al (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456:121-124
66. Huang W, Zuo T, Jin H, Liu Z, Yang Z, Yu X, Zhang L (2013a) Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors. Mol Diversity doi:10.1007/s11030-013-9424-3
67. Huang W, Zuo T, Luo X, et al. (2013b) Indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors. Chem Biol Drug Des doi:10.1111/cbdd.12119
68. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS (2011) Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85:11220-11234
69. Ikeda T, Abd El Galil KH, Tokunaga K et al (2011) Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons. Nucleic Acids Res 39:5538-5554
70. Ikeda T, Ohsugi T, Kimura T, Matsushita S, Maeda Y, Harada S, Koito A (2008) The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res 36:6859-6871
71. Ireton GC, Black ME, Stoddard BL (2003) The 1.14 A crystal structure of yeast cytosine deaminase: evolution of nucleotide salvage enzymes and implications for genetic chemotherapy. Structure 11:961-972 (Pubitemid 36966785)
72. Iwatani Y, Chan DS, Wang F et al (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35:7096-7108
73. Iwatani Y, Takeuchi H, Strebel K, Levin JG (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 80:5992-6002 (Pubitemid 43849177)
74. Jäger S, Cimermancic P, Gulbahce N et al (2012a) Global landscape of HIV-human protein complexes. Nature 481:365-370
75. Jäger S, Kim DY, Hultquist JF et al (2012b) Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375
76. Janini M, Rogers M, Birx DR, McCutchan FE (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 75:7973-7986 (Pubitemid 32743669)
77. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285-296 (Pubitemid 34211936)
78. Jern P, Coffin JM (2008) Effects of retroviruses on host genome function. Annu Rev Genet 42:709-732
79. Johansson E, Mejlhede N, Neuhard J, Larsen S (2002) Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 A resolution. Biochemistry 41:2563-2570 (Pubitemid 34168925)
80. Johansson E, Neuhard J, Willemoes M, Larsen S (2004) Structural, kinetic, and mutational studies of the zinc ion environment in tetrameric cytidine deaminase. Biochemistry 43:6020-6029 (Pubitemid 38669470)
81. Jonsson SR, LaRue RS, Stenglein MD, Fahrenkrug SC, Andresdottir V, Harris RS (2007) The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS ONE 2:e893
82. Kaiser SM, Emerman M (2006) Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol 80:875-882 (Pubitemid 43062899)
83. Kan NC, Franchini G, Wong-Staal F, DuBois GC, Robey WG, Lautenberger JA, Papas TS (1986) Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science 231:1553-1555 (Pubitemid 16050723)
84. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 77:11398-11407 (Pubitemid 37271638)
85. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K (2004) Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1:27
86. Kazazian HH Jr (2004) Mobile elements: drivers of genome evolution. Science 303:1626-1632 (Pubitemid 38338313)
87. Khan MA, Goila-Gaur R, Opi S, Miyagi E, Takeuchi H, Kao S, Strebel K (2007) Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 4:48
88. Khan MA, Kao S, Miyagi E et al (2005) Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 79:5870-5874 (Pubitemid 40548257)
89. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF (2005) G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 79:1975-1980 (Pubitemid 40459148)
90. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, Gross JD (2013) CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 Target Gene Expression. Molecular Cell Target Gene Expression.Molecular Cell 49:632-44
91. Kim U, Wang Y, Sanford T, Zeng Y, Nishikura K (1994) Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci USA 91:11457-11461 (Pubitemid 24356363)
92. Kinomoto M, Kanno T, Shimura M et al (2007) All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res 35:2955-2964 (Pubitemid 47073634)
93. Kitamura S, Ode H, Nakashima M et al (2012a) The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat Struct Mol Biol 19:1005-1010
94. Kitamura S, Ode H, Nakashima M et al (2012b) The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat Struct Mol Biol 19:1005-1010
95. Klemm L, Duy C, Iacobucci I et al (2009) The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 16:232-245
96. Ko TP, Lin JJ, Hu CY, Hsu YH, Wang AH, Liaw SH (2003) Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution. J Bio Chem 278:19111-19117 (Pubitemid 36799299)
97. Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T (2004) APOBEC3G targets specific virus species. J Virol 78:8238-8244 (Pubitemid 38944307)
98. Kohli RM, Abrams SR, Gajula KS, Maul RW, Gearhart PJ, Stivers JT (2009) A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J Bio Chem 284:22898-22904
99. Kohli RM, Maul RW, Guminski AF et al (2010) Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J Bio Chem 285:40956-40964
100. Konig R, Zhou Y, Elleder D et al (2008) Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135:49-60
101. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83:9474-9485
102. Lackey L, Demorest ZL, Land AM, Hultquist JF, Brown WL, Harris RS (2012) APOBEC3B and AID have similar nuclear import mechanisms. J Mol Biol 419:301-314
103. Lackey L, Law EK, Brown WL, Harris RS (2013) Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle 12:762-772
104. Land AM, Ball TB, Luo M et al (2008) Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 82:8172-8182
105. Langlois MA, Beale RC, Conticello SG, Neuberger MS (2005) Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res 33:1913-1923 (Pubitemid 41748336)
106. LaRue RS, Andrésdóttir V, Blanchard Y et al (2009) Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 83:494-497
107. LaRue RS, Jonsson SR, Silverstein KA et al (2008) The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol 9:104
108. Lecossier D, Bouchonnet F, Clavel F, Hance AJ (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112 (Pubitemid 36583087)
109. Lee TH, Coligan JE, Allan JS, McLane MF, Groopman JE, Essex M (1986) A new HTLVIII/LAV protein encoded by a gene found in cytopathic retroviruses. Science 231:1546-1549 (Pubitemid 16050721)
110. Lee YN, Bieniasz PD (2007) Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog 3:e10
111. Lee YN, Malim MH, Bieniasz PD (2008) Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol 82:8762-8770
112. Levanon EY, Eisenberg E, Yelin R et al (2004) Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol 22:1001-1005 (Pubitemid 39014477)
113. Lever AML, Jeang K-T, Berkhout B (2010) Recent advances in human retroviruses: principles of replication and pathogenesis: advances in retroviral research. World Scientific, Singapore, Hackensack
114. Li JB, Levanon EY, Yoon JK et al (2009) Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science 324:1210-1213
115. Li M, Shandilya SM, Carpenter MA et al (2012) First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol 7:506-517
116. Liddament MT, Brown WL, Schumacher AJ, Harris RS (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14:1385-1391 (Pubitemid 39081642)
117. Lindahl T (2000) Suppression of spontaneous mutagenesis in human cells by DNA base excision-repair. Mutat Res 462:129-135 (Pubitemid 30190220)
118. Lochelt M, Romen F, Bastone P et al (2005) The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci USA 102:7982-7987 (Pubitemid 40781049)
119. Loeb LA, Essigmann JM, Kazazi F, Zhang J, Rose KD, Mullins JI (1999) Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci USA 96:1492-1497 (Pubitemid 29098478)
120. Longerich S, Basu U, Alt F, Storb U (2006) AID in somatic hypermutation and class switch recombination. Curr Opin Immunol 18:164-174 (Pubitemid 43327298)
121. Losey HC, Ruthenburg AJ, Verdine GL (2006) Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA. Nat Struct Mol Biol 13:153-159 (Pubitemid 43214719)
122. Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol 78:11841-11852 (Pubitemid 39390771)
123. Maksakova IA, Romanish MT, Gagnier L, Dunn CA, van de Lagemaat LN, Mager DL (2006) Retroviral elements and their hosts: insertional mutagenesis in the mouse germ line. PLoS Genet 2:e2
124. Malim MH, Bieniasz PD (2012) HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med 2:a006940
125. Malim MH, Emerman M (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3:388-398 (Pubitemid 351784365)
126. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103 (Pubitemid 36834849)
127. Mariani R, Chen D, Schrofelbauer B et al (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31 (Pubitemid 36859838)
128. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9:1398-1403 (Pubitemid 37466189)
129. Martin KL, Johnson M, D'Aquila RT (2011) APOBEC3G complexes decrease human immunodeficiency virus type 1 production. J Virol 85:9314-9326
130. Mbisa JL, Barr R, Thomas JA et al (2007) Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 81:7099-7110 (Pubitemid 46986646)
131. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 279:7792-7798 (Pubitemid 38294663)
132. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol 81:13346-13353 (Pubitemid 350247831)
133. Morse DP, Aruscavage PJ, Bass BL (2002) RNA hairpins in noncoding regions of human brain and Caenorhabditis elegans mRNA are edited by adenosine deaminases that act on RNA. Proc Natl Acad Sci USA 99:7906-7911 (Pubitemid 34650978)
134. Muckenfuss H, Hamdorf M, Held U et al (2006) APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Bio Chem 281:22161-22172 (Pubitemid 44181920)
135. Münk C, Willemsen A, Bravo IG (2012) An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol 12:71
136. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553-563
137. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, Honjo T (1999) Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 274:18470-18476
138. Nathans R, Cao H, Sharova N et al (2008) Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 26:1187-1192
139. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15:166-170
140. Nik-Zainal S, Alexandrov LB, Wedge DC et al (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149:979-993
141. Nishikura K (2010) Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem 79:321-349
142. Nowarski R, Britan-Rosich E, Shiloach T, Kotler M (2008) Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol 15:1059-1066
143. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M (2008) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4:249-259
144. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T (2003) Constitutive expression of AID leads to tumorigenesis. J Exp Med 197:1173-1181 (Pubitemid 36570072)
145. Olson ME, Li M, Harris RS, Harki DA (2013) Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. ChemMedChem 8:112-117
146. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K (2007) Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradationresistant APOBEC3G variant. J Virol 81:8236-8246 (Pubitemid 47101509)
147. Opi S, Takeuchi H, Kao S et al (2006) Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol 80:4673-4682
148. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80:9259-9269 (Pubitemid 44359998)
149. Pak V, Heidecker G, Pathak VK, Derse D (2011) The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J Virol 85:8538-8547
150. Perez-Duran P, de Yebenes VG, Ramiro AR (2007) Oncogenic events triggered by AID, the adverse effect of antibody diversification. Carcinogenesis 28:2427-2433 (Pubitemid 350238943)
151. Petersen-Mahrt SK, Harris RS, Neuberger MS (2002) AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418:99-103 (Pubitemid 34742579)
152. Petit V, Guetard D, Renard M, Keriel A, Sitbon M, Wain-Hobson S, Vartanian JP (2009) Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J Mol Biol 385:65-78
153. Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J (1987) A novel form of tissuespecific RNA processing produces apolipoprotein-B48 in intestine. Cell 50:831-840
154. Ramiro AR, Jankovic M, Eisenreich T et al (2004) AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118:431-438 (Pubitemid 39485663)
155. Rathore A, Carpenter MA, Demir O, Ikeda T, Li M, Shaban N, Anokhin D, Law EK, Brown WL, Amaro R & Harris RS (2013) A single amino acid switches the intrinsic dinucleotide DNA cytosine deamination preference of APOBEC3G. Nucleic Acids Research, in preparation
156. Refsland EW, Hultquist JF, Harris RS (2012) Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T Cell Line CEM2n. PLoS Pathog 8:e1002800
157. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38:4274-4284
158. Roberts SA, Sterling J, Thompson C et al (2012) Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell 46:424-435
159. Rogozin IB, Iyer LM, Liang L et al (2007) Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase. Nat Immunol 8:647-656 (Pubitemid 46785129)
160. Rose KM, Marin M, Kozak SL, Kabat D (2005) Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res Hum Retroviruses 21:611-619 (Pubitemid 41113649)
161. Russell RA, Wiegand HL, Moore MD, Schafer A, McClure MO, Cullen BR (2005) Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J Virol 79:8724-8731 (Pubitemid 40934783)
162. Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J (2005) HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Bio Chem 280:8765-8775 (Pubitemid 40409564)
163. Sanville B, Dolan MA, Wollenberg K et al (2010) Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove. PLoS Pathog 6:e1000974
164. Sawyer SL, Emerman M, Malik HS (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2:E275
165. Sawyer SL, Emerman M, Malik HS (2007) Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog 3:e197
166. Schafer A, Bogerd HP, Cullen BR (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328:163-168 (Pubitemid 39349465)
167. Schumacher AJ, Haché G, MacDuff DA, Brown WL, Harris RS (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol 82:2652-2660 (Pubitemid 351329156)
168. Schumacher AJ, Nissley DV, Harris RS (2005) APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci USA 102:9854-9859 (Pubitemid 40993657)
169. Severi F, Chicca A, Conticello SG (2011) Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function. Mol Biol Evol 28:1125-1129
170. Shandilya SM, Nalam MN, Nalivaika EA et al (2010) Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18:28-38
171. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650
172. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9:1404-1407 (Pubitemid 37466190)
173. Shindo K, Li M, Gross PJ et al (2012) A comparison of two single-stranded DNA binding models by mutational analysis of APOBEC3G. Biology 1:260-276
174. Shlyakhtenko LS, Lushnikov AY, Li M, Lackey L, Harris RS, Lyubchenko YL (2011) Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J Bio Chem 286:3387-3395
175. Shlyakhtenko LS, Lushnikov AY, Miyagi A, Li M, Harris RS, Lyubchenko YL (2012) Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA. Biochemistry 51:6432-6440
176. Sodroski J, Goh WC, Rosen C, Tartar A, Portetelle D, Burny A, Haseltine W (1986) Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 231:1549-1553 (Pubitemid 16050722)
177. Song C, Sutton L, Johnson ME, D'Aquila RT, Donahue JP (2012) Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction. J Bio Chem 287:16965-16974
178. Soros VB, Yonemoto W, Greene WC (2007) Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog 3:e15
179. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS (2010) APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 17:222-229
180. Stenglein MD, Harris RS (2006) APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Bio Chem 281:16837-16841
181. Stenglein MD, Matsuo H, Harris RS (2008) Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol 82:9591-9599
182. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12:591-601 (Pubitemid 37222482)
183. Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA (1987) The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328:728-730 (Pubitemid 17125778)
184. Suspène R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP (2005) Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 102:8321-8326 (Pubitemid 40800087)
185. Svarovskaia ES, Xu H, Mbisa JL et al (2004) Human apolipoprotein B mRNA-editing enzymecatalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Bio Chem 279:35822-35828 (Pubitemid 39100589)
186. Tareen SU, Sawyer SL, Malik HS, Emerman M (2009) An expanded clade of rodent Trim5 genes. Virology 385:473-483
187. Teng B, Burant CF, Davidson NO (1993) Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260:1816-1819
188. Tian C, Wang T, Zhang W, Yu XF (2007) Virion packaging determinants and reverse transcription of SRP RNA in HIV-1 particles. Nucleic Acids Res 35:7288-7302
189. Turelli P, Mangeat B, Jost S, Vianin S, Trono D (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303:1829 (Pubitemid 38374868)
190. Unniraman S, Zhou S, Schatz DG (2004) Identification of an AID-independent pathway for chromosomal translocations between the Igh switch region and Myc. Nat Immunol 5:1117-1123 (Pubitemid 39549625)
191. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S (1994) G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci USA 91:3092-3096
192. von Schwedler U, Song J, Aiken C, Trono D (1993) Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 67:4945-4955 (Pubitemid 23215976)
193. Wang M, Rada C, Neuberger MS (2010) Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID. J Exp Med 207:141-153
194. Wang T, Tian C, Zhang W et al (2007) 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol 81:13112-13124 (Pubitemid 350156950)
195. Wang X, Abudu A, Son S, Dang Y, Venta PJ, Zheng YH (2011) Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J Virol 85:3142-3152
196. Wedekind JE, Dance GS, Sowden MP, Smith HC (2003) Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet 19:207-216 (Pubitemid 36398423)
197. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23:2451-2458 (Pubitemid 38954852)
198. Wissing S, Montano M, Garcia-Perez JL, Moran JV, Greene WC (2011) Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J Biol Chem 286:36427-36437
199. Xiang S, Short SA, Wolfenden R, Carter CW Jr (1997) The structure of the cytidine deaminaseproduct complex provides evidence for efficient proton transfer and ground-state destabilization. Biochemistry 36:4768-4774 (Pubitemid 27180957)
200. Xie K, Sowden MP, Dance GS, Torelli AT, Smith HC, Wedekind JE (2004) The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activationinduced deaminase and APOBEC-1. Proc Natl Acad Sci USA 101:8114-8119 (Pubitemid 38698063)
201. Yamanaka S, Balestra ME, Ferrell LD et al (1995) Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA 92:8483-8487
202. Yang B, Chen K, Zhang C, Huang S, Zhang H (2007) Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J Bio Chem 282:11667-11675 (Pubitemid 47100658)
203. Yeung ML, Houzet L, Yedavalli VS, Jeang KT (2009) A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J Biol Chem 284:19463-19473
204. Yu Q, Chen D, König R, Mariani R, Unutmaz D, Landau NR (2004a) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 279:53379-53386 (Pubitemid 40051843)
205. Yu Q, Konig R, Pillai S et al (2004b) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11:435-442 (Pubitemid 38568947)
206. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060 (Pubitemid 37386201)
207. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98 (Pubitemid 36834848)
208. Zhang J, Webb DM (2004) Rapid evolution of primate antiviral enzyme APOBEC3G. Hum Mol Genet 13:1785-1791 (Pubitemid 39173447)
209. Zhang W, Du J, Evans SL, Yu Y, Yu XF (2012) T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376-379
210. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78:6073-6076 (Pubitemid 38661697)
211. Zhou H, Xu M, Huang Q et al (2008) Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4:495-504
212. Zrenner R, Stitt M, Sonnewald U, Boldt R (2006) Pyrimidine and purine biosynthesis and degradation in plants. Annu Rev Plant Biol 57:805-836 (Pubitemid 44061046)